Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07152041 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Name: Newly-diagnosed Pediatric Ph-positive B-ALL Protocol — clinical trial record (NCT07152041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CAMS-Ph+ B-ALL

StatusRecruiting

PhasePhase 3

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2025-03-28

View on ClinicalTrials.gov ↗

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Lymphoblastic Leukemia (ALL)

873 trials monitored

See 52 trials at risk

This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol

Trial Details

NCT Number	NCT07152041
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Enrollment	150 participants
Start Date	2025-03-28
Primary Completion	2029-12 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-03